Payment overview · 2025
General Payments
$807.39
39 reported records · 15 companies
Healthcare provider profile · identity verified
Sanjay P Thakur, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WARTBURG, TN · NPI 1699816074
Verified facts
What the public records show
CMS Open Payments records show Sanjay P Thakur, M.D. received $807.39 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $279.85 | 34.7% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $136.36 | 16.9% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.28 | 8.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $69.72 | 8.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $49.54 | 6.1% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $37.32 | 4.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.03 | 2.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.73 | 2.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.17 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.74 | 2.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.73 | 2.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.23 | 2.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.65 | 2.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.68 | 1.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.36 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $807.39 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $230.93 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $138.38 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $123.58 | 1 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $123.58 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $84.81 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $72.28 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $69.72 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $68.71 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.55 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.55 | 5 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $37.32 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 106 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 119 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
119 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
115 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 491 | 129 |
| Gabapentin | Gabapentin | 471 | 90 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 377 | 62 |
| Omeprazole | Omeprazole | 338 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 304 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 73 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 261 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 203 | 51 |
| Oxycodone Hcl | Oxycodone Hcl | 191 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 190 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 183 | 53 |
| Lisinopril | Lisinopril | 179 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 167 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 33 |
| Metformin Hcl | Metformin Hcl | 142 | 41 |
| Furosemide | Furosemide | 131 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 131 | 25 |
| Promethazine Hcl | Promethazine Hcl | 128 | 59 |
| Farxiga | Dapagliflozin Propanediol | 119 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 115 | 28 |
| Glimepiride | Glimepiride | 114 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 27 |
| Alprazolam | Alprazolam | 107 | 26 |
| Eliquis | Apixaban | 106 | 25 |
| Azithromycin | Azithromycin | 101 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 94 | 21 |
| Naproxen | Naproxen | 93 | 31 |
| Carvedilol | Carvedilol | 86 | 24 |
| Potassium Chloride | Potassium Chloride | 86 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 17 |
| Allopurinol | Allopurinol | 80 | 19 |
| Pregabalin | Pregabalin | 75 | 13 |
| Montelukast Sodium | Montelukast Sodium | 72 | 17 |
| Bumetanide | Bumetanide | 71 | 24 |
| Trazodone Hcl | Trazodone Hcl | 71 | 22 |
| Spironolactone | Spironolactone | 66 | 23 |
| Losartan Potassium | Losartan Potassium | 65 | 18 |
| Sertraline Hcl | Sertraline Hcl | 64 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 16 |
| Ibuprofen | Ibuprofen | 60 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 50 |
| Meloxicam | Meloxicam | 57 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | suppressed |
| Jardiance | Empagliflozin | 55 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 16 |
| Famotidine | Famotidine | 53 | 16 |
| Nortriptyline Hcl | Nortriptyline Hcl | 53 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 16 |
| Benazepril Hcl | Benazepril Hcl | 50 | 16 |
| Mounjaro | Tirzepatide | 50 | 14 |
| Ondansetron Odt | Ondansetron | 50 | 20 |
| Temazepam | Temazepam | 50 | suppressed |
| Prednisone | Prednisone | 48 | 41 |
| Simvastatin | Simvastatin | 44 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 13 |
| Meclizine Hcl | Meclizine Hcl | 42 | 21 |
| Atenolol | Atenolol | 41 | 11 |
| Diazepam | Diazepam | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 13 |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 37 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 31 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 19 |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 27 | 11 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Lactulose | Lactulose | 23 | 14 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 13 |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Fluconazole | Fluconazole | 18 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Ramipril | Ramipril | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $807.39 · 39 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, ELIQUIS, ENHERTU, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, Kerendia, LifeVest, NURTEC ODT, QULIPTA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error